Federal contract award
75A50325F80003
OSELTAMIVIR PHOSPHATE (TAMIFLU) 30MG AND 75MG CAPSULES
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | ASPR/ORM-SNS |
| NAICS | 325412 — Pharmaceutical Preparation Manufacturing |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | 36F79723D0219 |
| Set-aside | Not reported |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $45.1M |
| Current contract value | $45.1M |
| Potential contract value / ceiling | $45.1M |
| Start date | Jan 30, 2025 |
| Current end date | Jun 6, 2025 |
| Potential end date | Jun 6, 2025 |
| Latest award activity | Mar 27, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 3 of 3 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Mar 27, 2026 | P00002 | $-187 | EOI::EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING::EOI TERMINATION FOR CONVENIENCE AGREEMENT AND CLOSEOUT MODIFICATION. |
| Jun 18, 2025 | P00001 | $-351.9M | OSELTAMIVIR PHOSPHATE (TAMIFLU) 30MG AND 75MG CAPSULES |
| Jan 29, 2025 | 0 | $397.0M | OSELTAMIVIR PHOSPHATE (TAMIFLU) 30MG AND 75MG CAPSULES |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.